# EDGAR Filing Document

**Accession Number:** 0001527728
**File Stem:** 0001731122-25-001297
**Filing Date:** 2025-9
**Character Count:** 16756
**Document Hash:** 281516400f6b2f569adbea771b9915f3
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001731122-25-001297.hdr.sgml**: 20250924

**ACCESSION NUMBER**: 0001731122-25-001297

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250918

**ITEM INFORMATION**: Material Modifications to Rights of Security Holders

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250924

**DATE AS OF CHANGE**: 20250924

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Lunai Bioworks Inc.
- **CENTRAL INDEX KEY:** 0001527728
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 452259340
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 0630

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38758
- **FILM NUMBER:** 251338840

**BUSINESS ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067
- **BUSINESS PHONE:** 45 39179840

**MAIL ADDRESS:**
- **STREET 1:** CENTURY CITY MEDICAL PLAZA
- **STREET 2:** 2080 CENTURY CITY EAST
- **CITY:** SUITE 906 LOS ANGELES
- **STATE:** CA
- **ZIP:** 90067

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO INC.
- **DATE OF NAME CHANGE:** 20240213

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** RENOVARO BIOSCIENCES INC.
- **DATE OF NAME CHANGE:** 20230807

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Enochian Biosciences Inc.
- **DATE OF NAME CHANGE:** 20230804

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION** **Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities ExchangeAct of 1934**

Date of Report (Date of earliest event reported): **September 18, 2025**

**<u>LUNAI BIOWORKS, INC.</u>**

(Exact name of registrant as specified in its charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-38751** | **45-2259340** |
| (State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |

---

**2080 Century Park East, Suite 906**

**LosAngeles, CA 90067**

(Address of principal executive offices)

**<u>+1(305) 918-1980</u>**

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the SecuritiesAct (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the ExchangeAct (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the ExchangeAct (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the ExchangeAct (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of theAct:

---

| | | |
|:---|:---|:---|
| **Title of Each Class** | **Trading Symbol** | **Name of Each Exchange on Which Registered** |
| Common Stock, par value $0.0001 per share | RENB | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 **Item 3.03 Material Modification to Rights of Security Holders.**

To the extent required by Item 3.03 of Form 8-K, the information contained in Item 5.03 of this Current Report on Form 8-K (this "C**urrent Report**") is incorporated herein by reference.

**Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year**

On September 18, 2025, Lunai Bioworks, Inc. (the "**Company**") filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the "**Certificate of Amendment**") with the Secretary of State of the State of Delaware to effect a 1-for-10 reverse stock split of the shares of the Company's common stock, par value $0.0001 per share (the "**Common Stock**"), either issued and outstanding or held by the Company as treasury stock, effective as of 12:01 a.m. (New York time) on September 29, 2025 (the "**Reverse Stock Split**").

On August 15, 2025, stockholders owning a majority of the outstanding voting capital stock of the Company entitled to vote thereon approved a corporate action by Special Meeting of Stockholders authorizing the Company's board of directors (the "**Board**") to amend the Company's certificate of incorporation, as amended, to effect a reverse stock split of all outstanding shares of Common Stock, by a ratio in the range of 1-for-3 to 1-for-10 to be determined in the Board's sole discretion. Following the approval of the stockholders, the Board determined to effect the Reverse Stock Split at a ratio of 1-for-10 and approved the filing of the Certificate of Amendment.

As a result of the Reverse Stock Split, every 10 shares of issued and outstanding Common Stock will be automatically combined into one issued and outstanding share of Common Stock, without any change in the par value per share. No fractional shares will be issued as a result of the Reverse Stock Split. Any fraction of a share of Common Stock outstanding that would be created as a result of the Reverse Stock split will be rounded up to the next whole share. The Reverse Stock Split will reduce the number of shares of Common Stock outstanding from 231,780,434 shares to approximately 23,178,096 shares, inclusive of adjustments for the rounding up of fractional shares. The number of authorized shares of Common Stock under the Certificate of Incorporation will remain unchanged at 350,000,000 shares and no changes will be made to the authorized or outstanding shares of preferred stock.

The Common Stock will begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market on September 30, 2025. The trading symbol for the Common Stock is "LNAI." The new CUSIP number for the Common Stock following the Reverse Stock Split is 29350E 203.

A press release announcing the split was published by the Company on September 24, 2025, a copy of which is filed herewith as Exhibit 99.1. For more information about the Reverse Stock Split, see the Company's notice of meeting and proxy statement on Form DEF 14A filed with the U.S. Securities and Exchange Commission on July 30, 2025. The information set forth herein is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is filed as Exhibit 3.1 to this Current Report and is incorporated by reference herein.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits.

---

| | |
|:---|:---|
| Exhibit Number | Description |
| 3.1 | [Certificate of Amendment to the Certificate of Incorporation of Lunai Bioworks, Inc.](e6874_ex3-1.htm) |
| 99.1 | [Press Release Announcing Reverse Stock Split, dated September 24, 2025.](e6874_ex99-1.htm) |
| 104 | Cover Page Interactive Date File (formatted as Inline XBRL) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **LUNAI BIOWORKS, INC.** | **LUNAI BIOWORKS, INC.** |
| By: | /s/ David Weinstein |
| Name: | David Weinstein |
| Title: | Chief Executive Officer |

---

Date:September 24, 2025

## Exhibit 3.1

**EXHIBIT 3.1**

**Lunai Bioworks, Inc. to Effect 10:1 Reverse Stock Split**

**Measure taken to Comply with Nasdaq Rule 5550(a)(2) Regarding Minimum Bid Price**

On August 15, 2025, the Company's stockholders approved a reverse stock split of the Company's Common Stock at a ratio of not less than 3:1 and no more than 10:1, with such ratio to be determined at the discretion of the Company's Board of Directors. The reverse stock split is intended to bring the Company into compliance with the minimum bid price requirement for continued listing on Nasdaq, although there is no assurance that the trading price for the Common Stock would remain over the continued listing requirements of Nasdaq in order to regain compliance with the Bid Price Requirement or sustain a continued listing of our Common Stock on the Nasdaq.

The 10:1 reverse stock split will automatically result in the conversion of ten (10) current shares of the Company's Common Stock into one (1) new share of Common Stock. Any fraction of a share of Common Stock outstanding that would be created as a result of the reverse stock split will be rounded up to the next whole share. Holders of the Company's Common Stock held in book-entry form or through a bank, broker or other nominee do not need to take any action in connection with the reverse stock split. Stockholders of record will be receiving information from the Company's transfer agent regarding their common stock ownership post-reverse stock split.

The reverse stock split is expected to reduce the number of shares of the Company's Common Stock outstanding on or about September 30, 2025, from approximately 231,780,434 shares to approximately 23,178,096 shares subject to some variability as a result of the fractional upward adjustments. Proportionate adjustments will be made to the exercise prices and the number of shares underlying the Company's outstanding equity awards, as applicable, as well as to the number of shares issuable under the Company's equity incentive plans and certain existing agreements. The Common Stock issued pursuant to the reverse stock split will remain fully paid and non-assessable. The reverse stock split will not affect the number of authorized shares of Common Stock.

Stockholders who hold shares electronically in book-entry form with Securities Transfer Corporation, the Company's transfer agent, will not need to take action to receive evidence of their shares of post-reverse stock split Common Stock.

Additional information about the reverse stock split can be found in the Company's definitive proxy statement filed with the Securities and Exchange Commission (the "SEC") on July 30, 2025 which is available free of charge at the SEC's website, www.sec.gov.

**About Lunai Bioworks, Inc.**:

Lunai Bioworks Inc. is an AI-powered drug discovery and biodefense company pioneering safe and responsible generative biology. With proprietary neurotoxicity datasets, advanced machine learning, and a focus on dual-use risk management, Lunai is redefining how artificial intelligence can accelerate therapeutic innovation while safeguarding society from emerging threats.

**Forward-Looking Statements**:

This press release contains "forward-looking statements" within the meaning of the Private Litigation Reform Act of 1995 regarding the plans and objectives of management for future operations and market trends and expectations. Forward-looking statements can be identified by the fact that they do not related strictly to historical or current facts. Forward-looking statements are based upon our current assumptions, expectations and beliefs concerning future developments and their potential effect on our business. In some cases, you can identify forward-looking statements by the following words: "may", "could", "would", "should", "expect", "intend", "plan", "anticipate", "believe", "approximately", "estimate", "predict", "project", "potential" or the negative of these terms or other comparable terminology, although the absence of these words does not necessarily mean that a statement is not forward-looking. A forward-looking statement is neither a prediction nor a guarantee of future events or circumstances, and those future events or circumstances may not occur. You should not place undue reliance on forward-looking statements, which speak only as of the date of this Press Release. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations and assumptions that involve numerous risks and uncertainties. Our plans and objectives are based, in part, on assumptions involving the continued expansion of our business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond our control. Lunai Bioworks encourages you to review the risk factors that may affect its future performance in its filings with the Securities and Exchange Commission. We are including this cautionary note to make applicable and take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 for forward-looking statements. We expressly disclaim any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Additional information respecting factors that could materially affect the Company and its operations are contained in the Company's filings with the SEC which can be found on the SEC's website at www.sec.gov.

For more information, please contact:

**Investor Contact**

Nathen Fuentes

Chief Financial Officer

investors@renovaro.com

www.renovarogroup.com

**SOURCE**: Lunai Bioworks, Inc.

## Exhibit 99.1

**EXHIBIT 99.1**

**CERTIFICATE OF AMENDMENT TO CERTIFICATE OF INCORPORATION**

**OF LUNAI BIOWORKS, INC**.

LUNAI BIOWORKS, INC., a corporation duly organized and existing under the General Corporation laws of the State of Delaware (the "**Corporation**"), does hereby certify as follows:

**ONE**: That the name of the Corporation is Lunai Bioworks, Inc. The original Certificate of Incorporation of the Corporation was filed with the Secretary of State of the State of Delaware on January 18, 2011 (the "***Certificate of Incorporation***").

**TWO**: That, the Board of Directors of the Corporation, adopted via unanimous written consent in accordance with Section 141 of the General Corporation Law of the State of Delaware, resolutions approving and declaring advisable that the Certificate of Incorporation be amended, as follows:

**RESOLVED**, that the following be added to Article Fifth of the Certificate of Incorporation to read as follows:

"Effective September 29, 2025 (the "***Effective Time***"), a 1-for-10 reverse stock split of the shares of the Corporation's common stock, par value $0.0001 per share (the "***Common Stock***"), shall become effective, pursuant to which each 10 shares of Common Stock outstanding and held of record by each stockholder of the Corporation (including treasury shares) immediately prior to the Effective Time shall be reclassified and combined into one validly issued, fully paid and non-assessable share of Common Stock, automatically and without any action on the part of the Corporation or the respective holders thereof upon the Effective Time, and shall thereupon represent one share of Common Stock from and after the Effective Time (such reclassification and combination of shares, the "***Reverse Stock Split***"). The par value of the Common Stock following the Reverse Stock Split shall remain at $0.0001 per share."

**THREE**: That stockholders holding majority of the Common Stock of the Corporation duly adopted, via a Special Meeting of Stockholders dated August 15, 2025 in accordance with Section 242 of the General Corporation Law of the State of Delaware, a reverse stock split in a range between 1-for-3 and 1-for-10 and authorized the Board of Directors to approve the exact ratio of the reverse stock split.

**IN WITNESS WHEREOF**, the Corporation has caused this Certificate of Amendment to be signed by its duly authorized officer this 18<sup>th</sup> day of September, and the foregoing facts stated herein are true and correct.

---

| | |
|:---|:---|
| **LUNAI BIOWORKS, INC.** | **LUNAI BIOWORKS, INC.** |
| By: |  |
| Name: | David Weinstein |
| Title: | Chief Executive Officer |

---